The round was led by XTX Ventures to support expansion across health and wellbeing markets.
"The demand for alternative pathways to access mental healthcare is enormous, and continues to grow by the day. We’re committed to disrupting traditional approaches to healthcare to help improve the quality of people’s lives, and we’re particularly focused on the perinatal mental health sector. With the support of XTX Ventures, Foresight Group and Praetura Ventures, we’ll strengthen the rollout of new clinical trials and product development, and champion the benefits of technology for reinforcing healthcare provision on a national, regional and global basis."
The financing round was led by Vitruvian Partners with participation from the Amazon Alexa Fund, XTX Ventures and the Northern Powerhouse Investment Fund.
"I am delighted to announce our latest fundraising round led by Vitruvian Partners. Vitruvian’s experience supporting high-growth and innovative technology companies globally will be invaluable as we continue to scale up our capabilities and operations. Given the evolving threat landscape and the increasingly sophisticated technology being used by adversarial actors, this investment will help us continue to stay at the forefront of the fight against misinformation, funding further research and development of end-to-end technology solutions that really break down and combat information threats."
The funding round was led by XTX Ventures to support intraday trading integration and European expansion.
"Despite its challenges, the past year has seen our business and sector thrive, demonstrating the increasing demand for investment services from businesses and their customers alike, and the growing shift to digital wealth. The new investment will help us bring our product to a wider audience and expand our platform and help us to achieve our goal of becoming the leading provider of API-based wealth and investment infrastructure across Europe."
Fitch Ventures led the Series A round to support the company as it expands its team and enters the US market.
"We are thrilled to be adding the resources and expertise of Fitch Group and XTX to the Cognitive Credit mission. Every day we strive to push the boundaries of what technology can do for credit investors, and we see huge opportunities to collaborate with our new strategic partners in this area. We have received phenomenal feedback from clients over the past year, and with this capital raise and near-term additions to the team, we couldn’t be more excited about our global expansion and further product roll-out in 2022."
The seed round was led by XTX Ventures and Prostate Cancer Research to support regulatory approvals and clinical studies.
"We are tremendously excited about the potential of this system to enhance our ability to detect cancer accurately and early. We are now looking forward to working with hospitals and radiology and urology partners to prove the technology and bring it into clinical use. Covid-19 has created a serious backlog in cancer screening and Lucida Medical is well placed to help us clear this and improve the care that we offer further over the coming years."
